The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Successful clinical trial execution begins with an end-to-end strategy: Expert insight series
Go inside Accelerator™ Drug Development to discover why successful clinical trial execution requires an end-to-end strategy that aligns clinical, regulatory, and supply teams and activities from the very start of study planning.
Successful clinical trial execution begins with an end-to-end strategy from day one rather than narrowly focusing on the next milestone. By gaining a clear understanding of the end goal from the outset and building the strategy around it, biotech and pharma companies can align on key priorities such as study feasibility, site selection, regulatory planning, and supply chain activities. This proactive approach creates a strong foundation for success and helps reduce delays as trials progress.
Coordinating work across multiple vendors is a common challenge in clinical trials
According to Jeremy Liska, Integrated Project Delivery Lead at Thermo Fisher Scientific, one of the most common challenges biotech and pharma sponsors face during clinical trial planning is coordinating work across multiple vendors that operate independently. Fragmented processes often lead to knowledge loss, siloed decision-making, and misaligned timelines—ultimately slowing progress. By integrating critical activities such as regulatory approvals, equipment readiness, laboratory supplies, and product availability from the beginning, drug developers can minimize delays and keep studies moving efficiently toward patients.
While there's naturally a heavy focus on study start-up and enrollment, it's important for sponsors to take time upfront to focus on long-term strategy. Anticipating later activities such as data cleaning, site inspections, and regulatory submissions allows teams to uncover hidden efficiencies, proactively manage risks, and accelerate key timelines. When cross-functional teams stay aligned from the start, they can respond more effectively to potential issues and keep execution on track.
What you'll learn in this video to improve your clinical trial execution:
- Think end-to-end from the start. Plan for the full clinical trial, not just the next milestone.
- Align early. Coordinating cross-functional planning upfront helps accelerate trial timelines.
- Integrate teams and services. Connected workflows reduce delays, complexity, and rework.
- Plan ahead. Looking beyond study start-up helps identify risks and improve efficiency.
- Stay connected. Collaboration across clinical, regulatory, and supply improves outcomes.
Expert:
Jeremy Liska, Integrated Project Delivery Lead at Thermo Fisher Scientific
Jeremy Liska is an Integrated Project Delivery Lead at Thermo Fisher Scientific, focused on connecting the planning and execution required to move clinical trials forward. His work brings together clinical operations, regulatory and supply considerations to align timelines, anticipate execution risks and identify opportunities for greater efficiency from study start-up through enrollment and downstream milestones.
This is part of a larger series, “Expert Perspective: Inside Accelerator™ Drug Development.” Watch the full video featuring seven industry-leading, cross-functional experts here.